UK HealthCare logo

Practice areas

  • Movement Disorders
  • Neurology

Faculty rank

Professor of Neurology; Molecular and Biomedical Pharmacology

Clinic information

Clinical interests

  • Epilepsy
  • Movement Disorders
  • Neurology

Education

Degree

West Virginia University, School of Medicine, Morgantown

Residency

University of Virginia Hospital, Charlottesville

Fellowship

Johns Hopkins Hospital, Baltimore

Certifications or Special training

American Board of Psychiatry and Neurology, Neurology 

Additional information

Profile
My name is John T. Slevin; I have appointments at the UK Albert B. Chandler Hospital and Lexington VA Medical Center where I specialize in the evaluation of disorders of movement. My clinical research interests center on Parkinson's disease and currently include several industry-sponsored clinical drug trials of promising new anti-Parkinson medications and NIH-funded translational research. I am director of Clinical Research at the UK Parkinson’s Disease Research Center of Excellence, the UK Holsinger Parkinson’s Disease Professor of Neuroscience, and Lexington VA Center Director of the VA National Parkinson’s Disease Consortium. My research laboratory is engaged in the study of molecular mechanisms of epileptogenesis. In this capacity, I hold the Robert & Jeanne Nyere Epilepsy Research Professorship. I have authored over 200 abstracts, book chapters and research articles. A member of several professional research and clinical national societies, I am an elected Fellow of the American Academy of Neurology and member of the American Neurological Association.

Research/Publications

  1. van Horne CG, Quintero JE, Gurwell JA, Wagner RP, Slevin JT, Gerhardt GA. Implantation of autologous peripheral nerve grafts into the substantia nigra of subjects with idiopathic Parkinson's disease treated with bilateral STN DBS: a report of safety and feasibility. J Neurosurg. 2016 May 6;1-8.
    View in: PubMed
  2. Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra K, Eaton S, Benesh JA. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. Mov Disord. 2016 Apr;31(4):530-7.
    View in: PubMed
  3. Lang AE, Rodriguez RL, Boyd JT, Chouinard S, Zadikoff C, Espay AJ, Slevin JT, Fernandez HH, Lew MF, Stein DA, Odin P, Fung VS, Klostermann F, Fasano A, Draganov PV, Schmulewitz N, Robieson WZ, Eaton S, Chatamra K, Benesh JA, Dubow J. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2016 Apr;31(4):538-46.
    View in: PubMed
  4. Lew MF, Slevin JT, Krüger R, Martínez Castrillo JC, Chatamra K, Dubow JS, Robieson WZ, Benesh JA, Fung VS. Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. Parkinsonism Relat Disord. 2015 Jul;21(7):742-8.
    View in: PubMed
  5. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology. 2012 Apr 17; 78(16):1229-36. PMID: 22496199.
    View in: PubMed
  6. Matveeva EA, Price DA, Whiteheart SW, Vanaman TC, Gerhardt GA, Slevin JT. Reduction of vesicle-associated membrane protein 2 expression leads to a kindling-resistant phenotype in a murine model of epilepsy. Neuroscience. 2012 Jan 27; 202:77-86. PMID: 22183055.
    View in: PubMed
  7. Matveeva EA, Davis VA, Whiteheart SW, Vanaman TC, Gerhardt GA, Slevin JT. Kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes correlates with enhanced glutamate release. Epilepsia. 2012 Jan; 53(1):157-67. PMID: 22150629.
    View in: PubMed
  8. Zaheer F, Slevin JT. Trichloroethylene and Parkinson disease. Neurol Clin. 2011 Aug; 29(3):657-65. PMID: 21803216.
    View in: PubMed
  9. Espay AJ, Dwivedi AK, Payne M, Gaines L, Vaughan JE, Maddux BN, Slevin JT, Gartner M, Sahay A, Revilla FJ, Duker AP, Shukla R. Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology. 2011 Apr 5; 76(14):1256-62. PMID: 21464430.
    View in: PubMed
  10. Blonder LX, Slevin JT. Emotional dysfunction in Parkinson's disease. Behav Neurol. 2011; 24(3):201-17. PMID: 21876260.
    View in: PubMed
  11. Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, DeStefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med. 2008; 6:32. PMID: 18986508.
    View in: PubMed
  12. McNicoll CF, Latourelle JC, MacDonald ME, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Saint-Hilaire MH, Massood T, Huskey KW, DeStefano AL, Gillis T, Mysore J, Goldwurm S, Pezzoli G, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord. 2008 Aug 15; 23(11):1596-601. PMID: 18649400.
    View in: PubMed
  13. DeStefano AL, Latourelle J, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts R, Guttman M, Racette BA, Perlmutter JS, Marlor L, Shill HA, Singer C, Goldwurm S, Pezzoli G, Saint-Hilaire MH, Hendricks AE, Gower A, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Hum Genet. 2008 Aug; 124(1):95-9. PMID: 18587682.
    View in: PubMed
  14. Matveeva EA, Vanaman TC, Whiteheart SW, Slevin JT. Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes. Epilepsia. 2008 Oct; 49(10):1749-58. PMID: 18513349.
    View in: PubMed
  15. Tobin JE, Latourelle JC, Lew MF, Klein C, Suchowersky O, Shill HA, Golbe LI, Mark MH, Growdon JH, Wooten GF, Racette BA, Perlmutter JS, Watts R, Guttman M, Baker KB, Goldwurm S, Pezzoli G, Singer C, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Laramie JM, DeStefano AL, Litvan I, Nicholson G, Corbett A, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Sherman S, Al-hinti J, Drasby E, Nance M, Moller AT, Ostergaard K, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology. 2008 Jul 1; 71(1):28-34. PMID: 18509094.
    View in: PubMed
  16. Gash DM, Rutland K, Hudson NL, Sullivan PG, Bing G, Cass WA, Pandya JD, Liu M, Choi DY, Hunter RL, Gerhardt GA, Smith CD, Slevin JT, Prince TS. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol. 2008 Feb; 63(2):184-92. PMID: 18157908.
    View in: PubMed
  17. Smith CD, Walton A, Slevin JT, Gerhardt GA, Umberger G, Smoot K, Schulze E, Gash D. Validation studies of the human movement analysis panel for hand/arm performance. J Neurosci Methods. 2007 Sep 30; 165(2):287-96. PMID: 17651810.
    View in: PubMed
  18. Slevin JT, Gash DM, Smith CD, Gerhardt GA, Kryscio R, Chebrolu H, Walton A, Wagner R, Young AB. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg. 2007 Apr; 106(4):614-20. PMID: 17432712.
    View in: PubMed
  19. Zhao C, Slevin JT, Whiteheart SW. Cellular functions of NSF: not just SNAPs and SNAREs. FEBS Lett. 2007 May 22; 581(11):2140-9. PMID: 17397838.
    View in: PubMed
  20. Wilk JB, Tobin JE, Suchowersky O, Shill HA, Klein C, Wooten GF, Lew MF, Mark MH, Guttman M, Watts RL, Singer C, Growdon JH, Latourelle JC, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Berg CJ, Sun M, Goldwurm S, Pezzoli G, Racette BA, Perlmutter JS, Parsian A, Baker KB, Giroux ML, Litvan I, Pramstaller PP, Nicholson G, Burn DJ, Chinnery PF, Vieregge P, Slevin JT, Cambi F, MacDonald ME, Gusella JF, Myers RH, Golbe LI. Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study. Neurology. 2006 Dec 26; 67(12):2206-10. PMID: 17190945.
    View in: PubMed
  21. Matveeva EA, Vanaman TC, Whiteheart SW, Slevin JT. Asymmetric accumulation of hippocampal 7S SNARE complexes occurs regardless of kindling paradigm. Epilepsy Res. 2007 Mar; 73(3):266-74. PMID: 17174072.
    View in: PubMed
  22. Ryan M, Slevin JT. Restless legs syndrome. Am J Health Syst Pharm. 2006 Sep 1; 63(17):1599-612. PMID: 16914630.
    View in: PubMed
  23. Caporello E, Nath A, Slevin J, Galey D, Hamilton G, Williams L, Steiner JP, Haughey NJ. The immunophilin ligand GPI1046 protects neurons from the lethal effects of the HIV-1 proteins gp120 and Tat by modulating endoplasmic reticulum calcium load. J Neurochem. 2006 Jul; 98(1):146-55. PMID: 16805804.
    View in: PubMed
  24. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Young AB. Reply: GDNF poses troubling questions for doctors, drug maker. Ann Neurol. 2006 Jun; 59(6):989-90. PMID: 16718700.
    View in: PubMed
  25. Slevin JT, Gash DM, Smith CD, Gerhardt GA, Kryscio R, Chebrolu H, Walton A, Wagner R, Young AB. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal. Neurosurg Focus. 2006; 20(5):E1. PMID: 16711657.
    View in: PubMed
  26. Penn RD, Dalvi A, Slevin J, Young B, Gash D, Gerhardt G, Hutchinson M. GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol. 2006 Mar; 5(3):202-3. PMID: 16488374.
    View in: PubMed
  27. Chebrolu H, Slevin JT, Gash DA, Gerhardt GA, Young B, Given CA, Smith CD. MRI volumetric and intensity analysis of the cerebellum in Parkinson's disease patients infused with glial-derived neurotrophic factor (GDNF). Exp Neurol. 2006 Apr; 198(2):450-6. PMID: 16455079.
    View in: PubMed
  28. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg. 2005 Feb; 102(2):216-22. PMID: 15739547.
    View in: PubMed
  29. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Research on Parkinson disease. J Neurosurg. 2005 Feb; 102(2):401. PMID: 15739575.
    View in: PubMed
  30. Nausieda PA, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease. Clin Ther. 2005 Jan; 27(1):58-63. PMID: 15763606.
    View in: PubMed
  31. Barnes GN, Slevin JT. Ionotropic glutamate receptor biology: effect on synaptic connectivity and function in neurological disease. Curr Med Chem. 2003 Oct; 10(20):2059-72. PMID: 12871085.
    View in: PubMed
  32. Matveeva EA, Whiteheart SW, Slevin JT. Accumulation of 7S SNARE complexes in hippocampal synaptosomes from chronically kindled rats. J Neurochem. 2003 Feb; 84(3):621-4. PMID: 12558983.
    View in: PubMed
  33. Haughey NJ, Nath A, Mattson MP, Slevin JT, Geiger JD. HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity. J Neurochem. 2001 Aug; 78(3):457-67. PMID: 11483648.
    View in: PubMed
  34. Blalock EM, Chen KC, Vanaman TC, Landfield PW, Slevin JT. Epilepsy-induced decrease of L-type Ca2+ channel activity and coordinate regulation of subunit mRNA in single neurons of rat hippocampal 'zipper' slices. Epilepsy Res. 2001 Mar; 43(3):211-26. PMID: 11248533.
    View in: PubMed
  35. Matveeva EA, Whiteheart SW, Vanaman TC, Slevin JT. Phosphorylation of the N-ethylmaleimide-sensitive factor is associated with depolarization-dependent neurotransmitter release from synaptosomes. J Biol Chem. 2001 Apr 13; 276(15):12174-81. PMID: 11278345.
    View in: PubMed
  36. Kluemper GT, White DK, Slevin JT. Chronic fissural cheilitis: a manifestation of anterior crowding. Am J Orthod Dentofacial Orthop. 2001 Jan; 119(1):71-5. PMID: 11174543.
    View in: PubMed
  37. Ryan M, Slevin JT, Wells A. Non-ergot dopamine agonist-induced sleep attacks. Pharmacotherapy. 2000 Jun; 20(6):724-6. PMID: 10853628.
    View in: PubMed
  38. Smith CD, Umberger GH, Manning EL, Slevin JT, Wekstein DR, Schmitt FA, Markesbery WR, Zhang Z, Gerhardt GA, Kryscio RJ, Gash DM. Critical decline in fine motor hand movements in human aging. Neurology. 1999 Oct 22; 53(7):1458-61. PMID: 10534251.
    View in: PubMed
  39. Smith-Swintosky VL, Kraemer PJ, Bruce AJ, McCants N, Maki A, Brown RW, Alcala M, Goodman Y, Slevin JT, Mattson MP. Bacterial alkaloids mitigate seizure-induced hippocampal damage and spatial memory deficits. Exp Neurol. 1996 Oct; 141(2):287-96. PMID: 8812162.
    View in: PubMed
  40. Barnes GN, Slevin JT, Vanaman TC. Rat brain protein phosphatase 2A: an enzyme that may regulate autophosphorylated protein kinases. J Neurochem. 1995 Jan; 64(1):340-53. PMID: 7798931.
    View in: PubMed
  41. Ryan SJ, Smith CD, Slevin JT. Magnetic resonance imaging in ochronosis, a rare cause of back pain. J Neuroimaging. 1994 Jan; 4(1):41-2. PMID: 8136578.
    View in: PubMed
  42. Shih WJ, Schleenbaker RE, Stipp V, Magoun S, Slevin JT. Surface and volume three-dimensional displays of Tc-99m HMPAO brain SPECT images in stroke patients by a three-headed gamma camera. Clin Nucl Med. 1993 Nov; 18(11):945-9. PMID: 8269673.
    View in: PubMed
  43. Duhr EF, Pendergrass JC, Slevin JT, Haley BE. HgEDTA complex inhibits GTP interactions with the E-site of brain beta-tubulin. Toxicol Appl Pharmacol. 1993 Oct; 122(2):273-80. PMID: 8212009.
    View in: PubMed
  44. Sparks DL, Hunsaker JC, Slevin JT, DeKosky ST, Kryscio RJ, Markesbery WR. Monoaminergic and cholinergic synaptic markers in the nucleus basalis of Meynert (nbM): normal age-related changes and the effect of heart disease and Alzheimer's disease. Ann Neurol. 1992 Jun; 31(6):611-20. PMID: 1355334.
    View in: PubMed
  45. Farrar YJ, Vanaman TC, Slevin JT. A phosphatase resistant substrate for the assay of protein kinase C in crude tissue extracts. Biochem Biophys Res Commun. 1991 Oct 31; 180(2):694-701. PMID: 1719969.
    View in: PubMed
  46. Jarvie PA, Logan TC, Geula C, Slevin JT. Entorhinal kindling permanently enhances Ca2(+)-dependent L-glutamate release in regio inferior of rat hippocampus. Brain Res. 1990 Feb 5; 508(2):188-93. PMID: 1968356.
    View in: PubMed
  47. Khatoon S, Campbell SR, Haley BE, Slevin JT. Aberrant guanosine triphosphate-beta-tubulin interaction in Alzheimer's disease. Ann Neurol. 1989 Aug; 26(2):210-5. PMID: 2774507.
    View in: PubMed
  48. Geula C, Slevin JT. Substantia nigra 6-hydroxydopamine lesions alter dopaminergic synaptic markers in the nucleus basalis magnocellularis and striatum of rats. Synapse. 1989; 4(3):248-53. PMID: 2532792.
    View in: PubMed
  49. Kadaba PK, Slevin JT. Triazolines XV. Anticonvulsant profile of ADD 17014, a potentially unique 1,2,3-triazoline antiepileptic drug, in mice and rats. Epilepsia. 1988 May-Jun; 29(3):330-7. PMID: 3371287.
    View in: PubMed
  50. Geula C, Jarvie PA, Logan TC, Slevin JT. Long-term enhancement of K+-evoked release of L-glutamate in entorhinal kindled rats. Brain Res. 1988 Mar 1; 442(2):368-72. PMID: 3370453.
    View in: PubMed
  51. Kasarskis EJ, Forrester TM, Slevin JT. Amygdalar kindling is associated with elevated zinc concentration in the cortex and hippocampus of rats. Epilepsy Res. 1987 Jul; 1(4):227-33. PMID: 3504398.
    View in: PubMed
  52. Slevin JT, Sparks DL, Dempsey RJ, Davis DG, Hunsaker JC, DeKosky ST. Altered striatal dopaminergic metabolism 36 hours after unilateral trauma to the human mesencephalon. Neurology. 1987 Feb; 37(2):322-5. PMID: 3808316.
    View in: PubMed
  53. Sparks DL, Slevin JT, Hunsaker JC. 3-Methoxytyramine in the putamen as a gauge of the postmortem interval. J Forensic Sci. 1986 Jul; 31(3):962-71. PMID: 3734746.
    View in: PubMed
  54. Sparks DL, Markesbery WR, Slevin JT. Alzheimer's disease: monoamines and spiperone binding reduced in nucleus basalis. Ann Neurol. 1986 Jun; 19(6):602-4. PMID: 2425718.
    View in: PubMed
  55. Slevin JT, DeKosky ST. Stability of sialogangliosides in kindled hippocampus. Exp Neurol. 1986 Jan; 91(1):208-11. PMID: 2866974.
    View in: PubMed
  56. Walker RF, Sparks DL, Slevin J, Rush ME. Temporal effects of norepinephrine on pineal serotonin in vitro. J Pineal Res. 1986; 3(1):33-40. PMID: 2420962.
    View in: PubMed
  57. Slevin JT, Kasarskis EJ, Vanaman TC, Zurini M. Excitatory amino acids and divalent cations in the kindling model of epilepsy. Adv Exp Med Biol. 1986; 203:587-98. PMID: 3024462.
    View in: PubMed
  58. Slevin JT, Ferrara LP. Lack of effect of entorhinal kindling on L-[3H]glutamic acid presynaptic uptake and postsynaptic binding in hippocampus. Exp Neurol. 1985 Jul; 89(1):48-58. PMID: 4007115.
    View in: PubMed
  59. Slevin JT, Kasarskis EJ. Effects of zinc on markers of glutamate and aspartate neurotransmission in rat hippocampus. Brain Res. 1985 May 20; 334(2):281-6. PMID: 2859913.
    View in: PubMed
  60. Slevin JT, Ferrara LP. Chronic valproic acid therapy and synaptic markers of amino acid neurotransmission. Neurology. 1985 May; 35(5):728-31. PMID: 3921873.
    View in: PubMed
  61. Sparks DL, Slevin JT. Determination of tyrosine, tryptophan and their metabolic derivatives by liquid chromatography-electrochemical detection: application to post mortem samples from patients with Parkinson's and Alzheimer's disease. Life Sci. 1985 Feb 4; 36(5):449-57. PMID: 3968972.
    View in: PubMed
  62. Sparks DL, Markesbery WR, Slevin JT. Age-associated alteration of serotonergic synaptic neurochemistry in rat rostral hypothalamus. Neurobiol Aging. 1985; 6(3):213-7. PMID: 2414677.
    View in: PubMed
  63. Sparks DL, Hunsaker JC, Slevin JT. Postmortem accumulation of 3-methoxytyramine in the brain. N Engl J Med. 1984 Aug 23; 311(8):540. PMID: 6749220.
    View in: PubMed
  64. Slevin JT, Collins JF, Coyle JT. Analogue interactions with the brain receptor labeled by [3H]kainic acid. Brain Res. 1983 Apr 11; 265(1):169-72. PMID: 6303506.
    View in: PubMed
  65. Slevin J, Collins J, Lindsley K, Coyle JT. Specific binding of [3H]L-glutamate to cerebellar membranes: evidence for recognition site heterogeneity. Brain Res. 1982 Oct 14; 249(2):353-60. PMID: 6128059.
    View in: PubMed
  66. Ferkany JW, Slevin JT, Zaczek R, Coyle JT. Failure of folic acid derivatives to mimic the actions of kainic acid in brain in vitro or in vivo. Neurobehav Toxicol Teratol. 1982 Sep-Oct; 4(5):573-9. PMID: 6129582.
    View in: PubMed
  67. Slevin JT, Johnston MV, Biziere K, Coyle JT. Methylazoxymethanol acetate ablation of mouse cerebellar granule cells: effects on synaptic neurochemistry. Dev Neurosci. 1982; 5(1):3-12. PMID: 6125372.
    View in: PubMed
  68. Slevin JT, Faught E, Hanna GR, Lee SI. Temporal relationship of EEG abnormalities in migraine to headache and medication. Headache. 1981 Nov; 21(6):251-4. PMID: 7309505.
    View in: PubMed
  69. Slevin JT, Coyle JT. Ontogeny of receptor binding sites for [3H]glutamic acid and [3H]kainic acid in the rat cerebellum. J Neurochem. 1981 Aug; 37(2):531-3. PMID: 6114990.
    View in: PubMed
  70. Coyle JT, Zaczek R, Slevin J, Collins J. Neuronal receptor sites for kainic acid: correlations with neurotoxicity. Adv Biochem Psychopharmacol. 1981; 27:337-46. PMID: 6255764.
    View in: PubMed
  71. Lepore FE, Sanborn GE, Slevin JT. Pupillary dysfunction in myasthenia gravis. Ann Neurol. 1979 Jul; 6(1):29-33. PMID: 228589.
    View in: PubMed